Clinical Study of the TriVascular Ovation™ Abdominal Stent Graft System
Primary Purpose
Aortic Aneurysm, Abdominal
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ovation™ Abdominal Stent Graft System
Sponsored by
About this trial
This is an interventional treatment trial for Aortic Aneurysm, Abdominal focused on measuring abdominal, aortic, aneurysm
Eligibility Criteria
Inclusion/Exclusion Criteria:
Inclusion Criteria
All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study:
- Patient is > 18 years of age
- Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)
- Patient has signed an Institutional Review Board (IRB) approved Informed Consent Form
- Patient is considered by the treating physician to be a candidate for elective open surgical repair of the abdominal aortic aneurysm (AAA) (i.e., category I, II, or III per American Society of Anesthesiology (ASA) classification. ASA category IV patients may be enrolled provided their life expectancy is greater than 1 year.
Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following:
- Abdominal aortic aneurysm ≥5.0 cm in diameter
- Aneurysm has increased in size by 0.5 cm in last 6 months.
- Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment
- Patient has patent iliac or femoral arteries that allow endovascular access with the TriVascular Ovation Abdominal Stent Graft System.
- Patient has a suitable non-aneurysmal proximal aortic neck length of ≥ 7 mm inferior to the most distal renal artery ostium.
- Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥10 mm. The resultant repair should preserve patency in at least one hypogastric artery.
- Patient has a suitable non-aneurysmal proximal aortic neck luminal diameter between 16 and 30 mm.
- Patient has suitable non-aneurysmal distal iliac luminal diameters between 8 and 20 mm.
- Patient meets the following anatomic criteria: the distance from the most distal renal artery to most superior internal iliac artery measurement is at least 13 cm.
- Patient has juxtarenal aortic neck angulation ≤ 60º if proximal neck is ≥10 mm and ≤ 45º if proximal neck is <10 mm.
- Patient must be willing to comply with all required follow-up exams.
Exclusion Criteria
Patients that meet ANY of the following are not eligible for enrollment into the study:
- Patient has a dissecting aneurysm
- Patient has an acutely ruptured aneurysm
- Patient has an acute vascular injury
- Patient has a need for emergent surgery
- Patient has a known thoracic aortic aneurysm or dissection.
- Patient has a mycotic aneurysm or has an active systemic infection
- Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)
- Patient has had a myocardial infarction (MI) and/or stroke (CVA) within the past 6 months.
- Patient has a major surgical or interventional procedure planned ≤30 days of the AAA repair.
- Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome).
- Patient has history of bleeding disorders or refuses blood transfusions.
- Patient has dialysis dependent renal failure or baseline serum creatinine level >2.0 mg/dl
- Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
- Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE), PEG-based polymers, fluorinated ethylene propylene (FEP) or nitinol.
- Patient has a body habitus that would inhibit X-ray visualization of the aorta
- Patient has a limited life expectancy of less than 1 year
- Patient is currently participating in another investigational device or drug clinical trial
- Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
Sites / Locations
- Community Care Physicians
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Ovation™ Abdominal Stent Graft System
Arm Description
Implant of Ovation™ Abdominal Stent Graft System
Outcomes
Primary Outcome Measures
The Primary Safety Endpoint is Defined as the Percentage of Subjects Who Experience a Major Adverse Event Within 30 Days of the Initial Procedure.
Major adverse events (MAE) are defined as any one of the following events:
Death
Myocardial Infarction
Stroke (excludes TIA)
Renal Failure (excludes renal insufficiency)
Respiratory Failure (excludes COPD or pulmonary complications)
Paralysis (excludes paraparesis)
Bowel Ischemia
Procedural Blood Loss (≥1,000 cc)
The Primary Effectiveness Endpoint is Percentage of Subjects That Achieve Treatment Success.
Treatment Success is a composite endpoint assessed at 12 months that requires the following criteria to be met:
Technical Success, defined as successful delivery and deployment of one aortic body and two iliac limbs.
Freedom from Type I & III endoleaks at 12 months
Freedom from stent graft migration at 12 months
Freedom from abdominal aortic aneurysm (AAA) enlargement at 12 months
Freedom from abdominal aortic aneurysm (AAA) rupture and conversion to open repair through 12 months
Endoleak Definition:
Type I - Ineffective seal at either the proximal or distal sealing zones Type II - Retrograde blood flow from lumbar arteries, the inferior mesenteric artery, or other collateral vessels into the aneurysm sac Type III - A leak caused by fabric tears or disruption, component disconnection, or graft disintegration Type IV - Blood flow through an intact fabric.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01092117
Brief Title
Clinical Study of the TriVascular Ovation™ Abdominal Stent Graft System
Official Title
A Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the Ovation™ Abdominal Stent Graft System
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
April 29, 2010 (Actual)
Primary Completion Date
December 20, 2017 (Actual)
Study Completion Date
December 20, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
TriVascular, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The primary objectives of this study are to determine whether the Ovation Abdominal Stent Graft System is a safe and effective method of treating abdominal aortic aneurysms (AAA's) in those patients considered to be suitable candidates for open surgical repair.
Detailed Description
This is a Phase II prospective, consecutive enrolling, non-randomized multi-center clinical evaluation of the safety and effectiveness of the Ovation Abdominal Stent Graft System when used in the treatment of patients with AAA (Treatment Group) as compared to a performance goal (Control Group).
150 study patients will be enrolled at up to 40 institutions. An additional 100 study patients will be enrolled in the continued access phase.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Aneurysm, Abdominal
Keywords
abdominal, aortic, aneurysm
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
161 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ovation™ Abdominal Stent Graft System
Arm Type
Other
Arm Description
Implant of Ovation™ Abdominal Stent Graft System
Intervention Type
Device
Intervention Name(s)
Ovation™ Abdominal Stent Graft System
Intervention Description
Implant of Ovation™ Abdominal Stent Graft System
Primary Outcome Measure Information:
Title
The Primary Safety Endpoint is Defined as the Percentage of Subjects Who Experience a Major Adverse Event Within 30 Days of the Initial Procedure.
Description
Major adverse events (MAE) are defined as any one of the following events:
Death
Myocardial Infarction
Stroke (excludes TIA)
Renal Failure (excludes renal insufficiency)
Respiratory Failure (excludes COPD or pulmonary complications)
Paralysis (excludes paraparesis)
Bowel Ischemia
Procedural Blood Loss (≥1,000 cc)
Time Frame
30 days
Title
The Primary Effectiveness Endpoint is Percentage of Subjects That Achieve Treatment Success.
Description
Treatment Success is a composite endpoint assessed at 12 months that requires the following criteria to be met:
Technical Success, defined as successful delivery and deployment of one aortic body and two iliac limbs.
Freedom from Type I & III endoleaks at 12 months
Freedom from stent graft migration at 12 months
Freedom from abdominal aortic aneurysm (AAA) enlargement at 12 months
Freedom from abdominal aortic aneurysm (AAA) rupture and conversion to open repair through 12 months
Endoleak Definition:
Type I - Ineffective seal at either the proximal or distal sealing zones Type II - Retrograde blood flow from lumbar arteries, the inferior mesenteric artery, or other collateral vessels into the aneurysm sac Type III - A leak caused by fabric tears or disruption, component disconnection, or graft disintegration Type IV - Blood flow through an intact fabric.
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion/Exclusion Criteria:
Inclusion Criteria
All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study:
Patient is > 18 years of age
Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)
Patient has signed an Institutional Review Board (IRB) approved Informed Consent Form
Patient is considered by the treating physician to be a candidate for elective open surgical repair of the abdominal aortic aneurysm (AAA) (i.e., category I, II, or III per American Society of Anesthesiology (ASA) classification. ASA category IV patients may be enrolled provided their life expectancy is greater than 1 year.
Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following:
Abdominal aortic aneurysm ≥5.0 cm in diameter
Aneurysm has increased in size by 0.5 cm in last 6 months.
Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment
Patient has patent iliac or femoral arteries that allow endovascular access with the TriVascular Ovation Abdominal Stent Graft System.
Patient has a suitable non-aneurysmal proximal aortic neck length of ≥ 7 mm inferior to the most distal renal artery ostium.
Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥10 mm. The resultant repair should preserve patency in at least one hypogastric artery.
Patient has a suitable non-aneurysmal proximal aortic neck luminal diameter between 16 and 30 mm.
Patient has suitable non-aneurysmal distal iliac luminal diameters between 8 and 20 mm.
Patient meets the following anatomic criteria: the distance from the most distal renal artery to most superior internal iliac artery measurement is at least 13 cm.
Patient has juxtarenal aortic neck angulation ≤ 60º if proximal neck is ≥10 mm and ≤ 45º if proximal neck is <10 mm.
Patient must be willing to comply with all required follow-up exams.
Exclusion Criteria
Patients that meet ANY of the following are not eligible for enrollment into the study:
Patient has a dissecting aneurysm
Patient has an acutely ruptured aneurysm
Patient has an acute vascular injury
Patient has a need for emergent surgery
Patient has a known thoracic aortic aneurysm or dissection.
Patient has a mycotic aneurysm or has an active systemic infection
Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)
Patient has had a myocardial infarction (MI) and/or stroke (CVA) within the past 6 months.
Patient has a major surgical or interventional procedure planned ≤30 days of the AAA repair.
Patient has history of connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome).
Patient has history of bleeding disorders or refuses blood transfusions.
Patient has dialysis dependent renal failure or baseline serum creatinine level >2.0 mg/dl
Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE), PEG-based polymers, fluorinated ethylene propylene (FEP) or nitinol.
Patient has a body habitus that would inhibit X-ray visualization of the aorta
Patient has a limited life expectancy of less than 1 year
Patient is currently participating in another investigational device or drug clinical trial
Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manish Mehta, MD
Organizational Affiliation
Albany Medical College
Official's Role
Principal Investigator
Facility Information:
Facility Name
Community Care Physicians
City
Latham
State/Province
New York
ZIP/Postal Code
12110
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
23978572
Citation
Mehta M, Valdes FE, Nolte T, Mishkel GJ, Jordan WD, Gray B, Eskandari MK, Botti C; A Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the Ovation Abdominal Stent Graft System Investigators. One-year outcomes from an international study of the Ovation Abdominal Stent Graft System for endovascular aneurysm repair. J Vasc Surg. 2014 Jan;59(1):65-73.e1-3. doi: 10.1016/j.jvs.2013.06.065. Epub 2013 Aug 24.
Results Reference
derived
Learn more about this trial
Clinical Study of the TriVascular Ovation™ Abdominal Stent Graft System
We'll reach out to this number within 24 hrs